Comparative Pharmacology
Head-to-head clinical analysis: BEPREVE versus LASTACAFT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BEPREVE versus LASTACAFT.
BEPREVE vs LASTACAFT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bepotastine besilate is a selective histamine H1 receptor antagonist. It inhibits histamine-induced vascular permeability, pruritus, and conjunctival inflammation.
Selective histamine H1 receptor antagonist; inhibits mast cell degranulation and reduces release of inflammatory mediators.
1 drop in the affected eye(s) twice daily (approximately every 6-8 hours).
1 drop in each affected eye twice daily (approximately every 8 hours)
None Documented
None Documented
Plasma elimination half-life is approximately 2-3 hours in healthy adults. In patients with renal impairment, half-life may be prolonged (up to 6-8 hours in severe impairment).
Terminal elimination half-life is approximately 2 hours; clinically, dosing is twice daily.
Bepotastine besilate is primarily excreted via renal elimination. Approximately 75-80% of the administered dose is eliminated unchanged in the urine, with less than 10% recovered in feces. Minor biliary excretion occurs.
Renal: approximately 70% as unchanged drug; fecal: approximately 30% as metabolites.
Category C
Category C
Ophthalmic Antihistamine
Ophthalmic Antihistamine